Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Standard BioTools (LAB) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
LAB - Standard BioTools Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$3.25
DETAILS
HIGH:
$3.25
LOW:
$3.25
MEDIAN:
$3.25
CONSENSUS:
$3.25
UPSIDE:
215.53%
Stock News
Standard BioTools Reports First Quarter 2026 Financial Results
BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.
Reviewing Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)
Standard BioTools (NASDAQ: LAB - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 53.7% of Standard BioTools
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
BOSTON, Mass. , April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U. S. market close.
PPJ Enterprise (OTCMKTS:PPJE) and Standard BioTools (NASDAQ:LAB) Financial Comparison
Standard BioTools (NASDAQ: LAB - Get Free Report) and PPJ Enterprise (OTCMKTS:PPJE - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership. Volatility and Risk Standard BioTools has a
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.
Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday
Standard BioTools (NASDAQ: LAB - Get Free Report) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Standard BioTools Completes Sale of SomaLogic to Illumina
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments
Standard BioTools (NASDAQ:LAB) versus Clover Health Investments (NASDAQ:CLOV) Critical Review
Standard BioTools (NASDAQ: LAB - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Profitability This table compares Standard BioTools